Video

Dr. Ginsburg on Genetic Testing in Ovarian Cancer Families

Ophira M. Ginsburg, MSc, MD, FRCPC, director of the High-Risk Cancer Program, Perlmutter Cancer Center at NYU Langone Medical Center, discusses the importance of genetic testing in ovarian cancer families.

Ophira M. Ginsburg, MSc, MD, FRCPC, director of the High-Risk Cancer Program, Perlmutter Cancer Center at NYU Langone Medical Center, discusses the importance of genetic testing in ovarian cancer families.

In cases of ovarian cancer families that test negative for BRCA 1/2 mutations, practitioners are beginning to offer multi-gene panel testing, which includes Lynch syndrome genes and others associated with hereditary nonpolyposis colon cancer that be detected in other gynecologic cancers, including ovarian cancer and uterine cancer, Ginsburg explains.

If a Lynch syndrome gene is detected in families with colon cancer, then women should be counseled for predictive testing. Options for risk reduction should include hysterectomy as well as bilateral salpingo-oophorectomy, Ginsburg concludes.

Related Videos
Jennifer Scalici, MD
Steven H. Lin, MD, PhD
Anna Weiss, MD, associate professor, Department of Surgery, Oncology, associate professor, Cancer Center, University of Rochester Medicine
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Victor Moreno, MD, PhD
Tiago Biachi, MD, PhD
Dr Girard on De Novo and Acquired Resistance Alterations in HER2-Altered NSCLC
Elias Jabbour, MD
Daniel DeAngelo, MD, PhD
Douglas W. Sborov, MD, MS